Eversense is designed as an implantable, long-term CGM device for continuous measurement of interstitial fluid glucose levels. The system then wirelessly transmits the readings to a smartphone app.
The purpose of adopting this system into the iLet is to enable real-time Eversense data to serve as a CGM option to drive the fully autonomous bionic pancreas.
Senseonics president and CEO Tim Goodnow said: “The combination of these two technologies could create a unique option for increased simplicity, convenience and confidence in diabetes management.
“We are pleased to be working with the Beta Bionics team as they advance a real breakthrough for people with diabetes.”
Beta Bionics is developing the dual-chamber, infusion pump iLet system to duplicate a biological pancreas via automatic and autonomous adjustment of insulin and glucagon dosing in order to meet the individual requirements of diabetes patients.
Beta Bionics president and CEO Ed Damiano said: “Senseonics has generated impressive clinical data demonstrating the remarkable accuracy of their Eversense CGM system and providing a categorically different CGM alternative for people with diabetes.
“We are excited to partner with Senseonics to help make the iLet Bionic Pancreas system a platform of choice for people with diabetes – one that will ultimately allow people to choose between multiple CGMs, to choose between multiple insulin types, and to choose glucagon.”